An anticancer agent icaritin induces sustained activation of the extracellular signal-regulated kinase (ERK) pathway and inhibits growth of breast cancer cells

Department of Medical Microbiology and Immunology, Creighton University Medical School, 2500 California Plaza, Omaha, NE 68178, USA.
European journal of pharmacology (Impact Factor: 2.68). 03/2011; 658(2-3):114-22. DOI: 10.1016/j.ejphar.2011.02.005
Source: PubMed

ABSTRACT Icaritin, a prenylflavonoid derivative from Epimedium Genus, regulates many cellular processes. However, the function and the underlying mechanisms of icaritin in breast cancer cell growth have not been well established. Here, we report that icaritin strongly inhibited the growth of breast cancer MDA-MB-453 and MCF7 cells. At concentrations of 2-3 μM, icaritin induced cell cycle arrest at the G(2)/M phase accompanied by a down-regulation of the expression levels of the G(2)/M regulatory proteins such as cyclinB, cdc2 and cdc25C. Icaritin at concentrations of 4-5 μM, however, induced apoptotic cell death characterized by the accumulation of the annexin V- and propidium iodide-positive cells, cleavage of poly ADP-ribose polymerase (PARP) and down-regulation of the Bcl-2 expression. In addition, icaritin also induced a sustained phosphorylation of extracellular signal-regulated kinase (ERK) in these breast cancer cells. U0126, a specific ERK activation inhibitor, abrogated icaritin-induced G2/M cell cycle arrest and cell apoptosis. Icaritin more potently inhibited growth of the breast cancer stem/progenitor cells compared to anti-estrogen tamoxifen. Our results indicate that icaritin is a potent growth inhibitor for breast cancer cells and provide a rationale for preclinical and clinical evaluations of icaritin for breast cancer therapy.

Download full-text


Available from: Xintian Zhang, Dec 02, 2014
1 Follower
  • Source
    • "Activation of p38 kinase mediates the TNF␣-induced expression of vascular cell adhesion molecule (VCAM)-1, which are expressed by articular chondrocytes as well as synovial and endothelial cells [40]. In the other investigations, they demonstrated that transient activation of ERK plays a pivotal role in cell proliferation, and that sustained ERK activation induces cell cycle and differentiation [41] [42]. SFN also decreased the expression of COX-2, via p38 signaling pathway in bladder T-24 cancer cell [43]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Sulforaphane (SFN), a member of the isothiocyanate family, is a biologically active compound extracted from cruciferous vegetables such as broccoli, cauliflower, radishes and cabbage. Although it possesses potent anti-inflammatory and anticancer properties, the specific effects and detailed mechanisms of SFN remain poorly understood. To investigate whether SFN regulates dedifferentiation and inflammation, chondrocytes were treated with SFN, which induced dedifferentiation and reduced inflammation, as indicated by the reduction of type II collagen and cyclooxygenase-2 (COX-2) in a dose- and time-dependent manner, as determined by Western blot analysis and RT-PCR. Synthesis of sulfated proteoglycan and production of prostaglandin E2 (PGE2) were decreased by treatment of SFN, as was detected by Alcian blue staining and immunohistochemical staining, and immunofluorescence staining and PGE2 assay, respectively. Additionally, treatment of SFN stimulated activation of mitogen-activated protein kinases (MAPKs), extracellular signal-regulated-kinase (ERK-1/2) and p38 kinase. Inhibition of ERK-1/2 with PD98059 rescued SFN-induced a loss of type II collagen expression, whereas inhibition of p38 kinase with SB203580 recovered SFN-reduced COX-2 expression, as determined by the Western blot analysis, immunohistochemical staining and immunofluorescence staining. Taken together, these results indicate that SFN regulates type II collagen via ERK-1/2 and COX-2 expression via p38kinase in rabbit articular chondrocytes.
    01/2013; 3(1):91–97. DOI:10.1016/j.bionut.2012.10.012
  • Source
    • "Prenylflavonoid derivatives are recognized as the major bioactive constituents of the herb, which can be hydrolyzed to its metabolites, including icaritin (ICT, Fig. 1), by intestinal enzyme (Liu et al., 2005; Qiu et al., 1999; Shen et al., 2007, 2009). Modern pharmacology studies demonstrated that this deglycosylated aglycone ICT exerts many pharmacological activities, including reduction of incidence of steroid-associated osteonecrosis in rabbits with inhibition of both thrombosis and lipid-deposition (Zhang et al., 2009); enhancement of osteoblastic differentiation and suppression of osteoclastic differentiation (Huang et al., 2007a,b); protection of primary cultured rat neuronal cells against the A␤ 25–35i -induced toxicity (Wang et al., 2007); stimulation of neuronal and cardiomyocyte differentiations from mouse embryonic stem cells in vitro (Wang et al., 2009; Wo et al., 2008; Zhu and Lou, 2005); as well as inhibition of growth of human prostate carcinoma PC-3 cell (Huang et al., 2007a,b), breast cancer cells (Guo et al., 2011) and endometrial cancer cells (Tong et al., 2011). Even several publications have reported the ICT plasma concentrations in animals (Shen et al., 2009; Wong et al., 2009) and in human (Shen et al., 2007) after consumption of a crude extract from Epimedium species in which ICT was mostly presented as "
    [Show abstract] [Hide abstract]
    ABSTRACT: Icaritin (ICT) is a main aglycone and also active intestinal metabolite of prenylflavonoids from the Chinese medicine Herba Epimedii. In the present study, the oral absorption and excretion of this compound was investigated using rats for exploring its fate in the body, so as to better understanding its in vivo pharmacological activities. The free (parent) and total (parent plus conjugated metabolites) ICT concentrations in rat plasma, urine and bile, after intravenous (i.v.) and oral administration both at 5mg/kg, were determined before and after enzymatic hydrolysis with β-glucuronidase/sulphatase, respectively, by a HPLC-UV method. The results showed that free ICT plasma concentration after i.v. dose was rapidly decreased with average t(1/2, λ) of 0.43 h, while the total ICT concentration was decreased slowly with t(1/2, λ) of 6.86 h. The area under the curve of ICT conjugated metabolites was about 11-fold higher than that of free ICT. The majority of ICT in the body was excreted from the bile with 68.05% of dose over 8 h after i.v. dosing, in which only 0.15% was in parent form. While very little amount of ICT was excreted from the urine with 3.01% of dose over 24 h, in which the parent form was 0.62%. After oral administration, very little amount of parent ICT was detected only in 0.5, 1 or 2 h plasma samples with the concentration less than LOQ, however, its total plasma concentration after enzymatic hydrolysis treatment was at relative high level with average maximum concentration of 0.49 μg/ml achieved at 1h post dose. The oral bioavailability of ICT was 35% of dose, estimated by its total plasma drug concentrations. It is concluded that ICT can be easily absorbed into the body, and then rapidly conversed to its conjugated metabolites, and finally removed from the body mainly by biliary excretion.
    Phytomedicine: international journal of phytotherapy and phytopharmacology 07/2012; 19(11):1024-8. DOI:10.1016/j.phymed.2012.05.017 · 2.88 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: There is concern that ingestion of dietary phytoestrogens may increase risk of estrogen receptor alpha (ERα)-positive breast cancer. The prenylflavone icaritin, a phytoestrogen consumed in East Asian societies for its perceived beneficial effects on bone health, stimulated the growth of breast cancer (MCF-7) cells at low concentrations. Although acting like an estrogenic ligand, icaritin exerted an unexpected suppressive effect on estrogen-stimulated breast cancer cell proliferation and gene expression at higher concentrations. Like estradiol, icaritin could dose-dependently destabilize ERα protein. However, destabilization of ERα by the estradiol/icaritin combination was profound and greater than that observed for either compound alone. Microarray gene expression analyses implicated aryl hydrocarbon receptor (AhR) signaling for this suppressive effect of icaritin. Indeed, icaritin was an AhR agonist that competitively reduced specific binding of a potent AhR agonist and increased expression of the AhR-regulated gene CYP1A1. When AhR was knocked down by small interfering RNA, the suppressive effect of icaritin on estradiol-stimulated breast cancer cell growth and gene expression was abolished, and ERα protein stability was partially restored. Similarly in an athymic nude mouse model, icaritin restricted estradiol-stimulated breast cancer xenograft growth and strongly reduced ERα protein levels. Overall, our data support the feasibility for the development of dual agonists like icaritin, which are estrogenic but yet, through activating AhR-signaling, can destabilize ERα protein to restrict ERα-positive breast cancer cell growth.
    Carcinogenesis 03/2012; 33(5):1089-97. DOI:10.1093/carcin/bgs110 · 5.27 Impact Factor
Show more